Abstract Details

Title Quality of Life in Sexual and Gender Minorities: A Pioneer Cross-sectional Study

Topic Health Care Disparities

Presentation(s) P3 - Poster Session 3 (5:30 PM-6:30 PM)

Poster/Presentation
Number 4-010

Background SGM people account for 8% of the total American adult population.¹ Nonetheless, epilepsy data regarding SGM people are scarce.² Data on physical and mental quality of life (QOL) aspects among SGM people with epilepsy (PWE) are unknown.

Objective Determine quality of life characteristics among sexual and gender minority (SGM) people living with epilepsy.

Design/Methods As part of a quality improvement initiative, data was collected using electronic patient-report questionnaires from January 2019 to September 2023 in a tertiary epilepsy clinic. We analyzed PWE’s physical and mental QOL aspects using the PROMIS-10 questionnaire. We categorized patients by sexual orientation and gender identity. Descriptive statistics were performed comparing SGM patients to cisgender heterosexual patients.

Results Data regarding sexual orientation was available for 2230 patients, of whom 164 (7.35%) identified as sexual minority people. Data regarding gender identity was available for 2623 patients, of whom 24 (0.91%) identified as transgender. Only 25 SGM (including 3 transgender) patients and 433 cisgender heterosexual patients completed PROMIS 10 questionnaires. Among cisgender heterosexual patients, median values from mental and physical sections of PROMIS 10 were 45.8 (IQR 14.5) and 50.8 (IQR 15.4) respectively. Median values among all SGM patients were 41.1 (IQR 14.5) and 47.7 (IQR 11.8) respectively. Median values among sexual minority patients were 43.55 (IQR 25.2) and 46.3 (IQR 14.85), respectively. Median values among transgender people were 53.30 (IQR 37.8) and 42.30 (IQR 15.9), respectively

Conclusions

Our data suggest different QOL metrics when stratified by gender identity and sexual orientation. No test of significance was performed due to the high rates of missing data, which calls for further research to improve data completion that may reveal healthcare disparities among SGM people.

Authors/Disclosures
Levi Coelho Maia Barros, MD (Massachusetts General Brigham) PRESENTER	Mr. Coelho Maia Barros has received publishing royalties from a publication relating to health care. Mr. Coelho Maia Barros has received personal compensation in the range of $10,000-$49,999 for serving as a Primary Care Physician with Secretaria Municipal de Saúde de Fortaleza, Ceará, Brazil.
Aya ElHassan (MGH)	No disclosure on file
Julianne Brooks	No disclosure on file
Caroline Banfi (MGH)	No disclosure on file
Maria Donahue (Massachusetts General Hospital)	No disclosure on file
Chelsea Wong (Hebrew SeniorLife)	No disclosure on file
Z P. L'Erario, MD, LMSW	Dr. L'Erario has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Ohio State University, University of Colorado, Sacred Heart University, The LOFT LGBT Community Center, Oregon Stroke Conference, Child Neurology Society. Dr. L'Erario has received personal compensation in the range of $5,000-$9,999 for serving as an Expert Witness for Weiss Law. Dr. L'Erario has received publishing royalties from a publication relating to health care.
Alison Kukla (Epilepsy Foundation of America)	No disclosure on file
Brandy Fureman, PhD	Dr. Fureman has received personal compensation for serving as an employee of Epilepsy Foundation. The institution of Dr. Fureman has received research support from PCORI/Cincinnati Children's Hospital Medical Center. The institution of Dr. Fureman has received research support from PCORI. The institution of Dr. Fureman has received research support from UCB Biopharma SPRL. The institution of Dr. Fureman has received research support from CDC.
Jeffrey R. Buchhalter, MD, FAAN (Buchhalter Consulting PLLC)	Dr. Buchhalter has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Epilepsy Foundation. Dr. Buchhalter has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Epilepsy Study Consortium. Dr. Buchhalter has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Epilog. Dr. Buchhalter has received personal compensation in the range of $500-$4,999 for serving as a Consultant for UCB. Dr. Buchhalter has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Shackelford Pharmaceuticals. Dr. Buchhalter has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biocodex. Dr. Buchhalter has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for UCB. Dr. Buchhalter has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biocodex.
Sahar Zafar, MD	Dr. Zafar has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Corticare. Dr. Zafar has received research support from NIH. Dr. Zafar has received personal compensation in the range of $5,000-$9,999 for serving as a Speaker for a lecture with Marinus.
Lidia Maria V. Moura, MD, PhD, MPH, FAAN (Massachusetts General Hospital)	Dr. Moura has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for eNova. Dr. Moura has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Epilepsy Foundation. The institution of Dr. Moura has received research support from NIH-NIA - 1K08AG053380-01A1. The institution of Dr. Moura has received research support from NIH-NIA 5R01AG062282-02 . The institution of Dr. Moura has received research support from NIH-NIA 2P01AG032952-11 . The institution of Dr. Moura has received research support from NIH- NIA 3R01AG062282-03S1 . The institution of Dr. Moura has received research support from Centers for Diseases Control and Prevention (CDC SIP20-007) . The institution of Dr. Moura has received research support from Epilepsy Foundation of America .